A real‐world Australian experience of upadacitinib for the treatment of severe atopic dermatitis-Reference-Cited by-同舟云学术

A real‐world Australian experience of upadacitinib for the treatment of severe atopic dermatitis

Published:2023-07-31 Issue:4 Volume:64 Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Tran Vanessa¹^ORCID,Ross Gayle¹²

Affiliation:

1. Department of Dermatology Royal Melbourne Hospital Parkville Victoria Australia

2. Department of Medicine University of Melbourne Parkville Victoria Australia

Abstract

AbstractUpadacitinib is a selective Janus kinase‐1 (JAK‐1) inhibitor that has been shown in clinical trials to be effective for the treatment of moderate‐to‐severe atopic dermatitis (AD). This study aimed to evaluate the real‐world experience of patients with AD treated with upadacitinib in a single‐centre Australian cohort. Our study revealed a higher propensity for herpetic infections compared with previous randomised controlled trials (RCTs).

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14139

Reference11 articles.

1. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

2. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

3. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

4. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

5. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks;Frontiers in Immunology;2024-04-30

2. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study;Journal of Dermatological Treatment;2024-04-23

3. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan;Clinical Drug Investigation;2024-03-06

4. Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review;Clinical, Cosmetic and Investigational Dermatology;2024-03

5. Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis;Journal of Dermatological Treatment;2024-01-31